Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 47 clinical trials
A Study of the Kinetics of Lymphoid Cells in Patients with Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers

have not been taking certain agents (Viagra, Levitra, Cialis, or other PDE-inhibitors, prednisone, cyclosporin-A, rapamycin, or other immunosuppressive agents, more than 2 cups of green tea daily, or

mantle cell lymphoma
chronic lymphocytic leukemia
  • 15 Apr, 2019
  • 1 location
Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

The primary aims of this study is to determine the efficacy and tolerability of Extracorporeal Photopheresis (ECP) for the treatment of either refractory (240) or newly diagnosed (739) Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation.In compliance with the Centers for Medicare and Medicaid Services' (CMS) Coverage with Evidence …

  • 24 Jan, 2021
  • 21 locations
Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome

steroids is uesful for primary nephrotic syndrome, proning to cause frequent relapse/steroid-dependent nephrotic syndrome after treatment, and the usage of immunosuppressive agents has become a new choice

  • 25 Nov, 2020
  • 9 locations
Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells

Chronic Graft-versus-Host Disease (cGvHD) is a potentially lethal disorder. A variety of second line immunosuppressive agents have been investigated but no optimal treatment has emerged. There

immunosuppressive agents
cell transplantation
  • 07 Nov, 2020
  • 1 location
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant

Immunosuppressive therapy is required to prevent organ rejection, however, dosing of immunosuppressive agents is complicated by patient-specific differences impacting the body's absorption and

  • 05 Nov, 2020
  • 2 locations
Role of Famotidine in the Symptomatic Improvement of COVID-19 Patients

novel virus; there is no specific medication against it. Like other countries of the world, Besides antiviral drugs, immunosuppressive agents, and symptomatic therapy like H2 receptor blocker FAMOTIDINE

antiviral drugs
chest ct
  • 24 Jan, 2021
  • 2 locations
Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT

immunosuppressive agents such as glucocorticoids will be added in. However, too intensive immunosuppressive measures leave the patients susceptible to infection and, in turn, increases the accidence of non-relapse

tissue damage
graft versus host disease
clot formation
hematologic disorders
hemorrhagic cystitis
  • 24 Jan, 2021
  • 1 location
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

This is a prospective, randomized, single clinical study designed to evaluate its safety and efficacy by using Microwave Ablation combine with Pembrolizumab in patients with Stage BNon -small Cell Lung.Cancer (NSCLC) who failed with first-line therapy.

cancer treatment
measurable disease
secondary malignant neoplasm of liver
  • 24 Jan, 2021
  • 1 location
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia

Aplastic anemia is a rare autoimmune disorder in which the bone marrow production of blood cells is greatly decreased or absent. Symptoms include fatigue, weakness, tiny reddish-purple marks on the skin, abnormal bruising, and bleeding from the gums, nose, or intestine. While some cases of aplastic anemia are caused by …

reticulocyte count
severe aplastic anemia
neutrophil count
aplastic anemia
  • 07 Nov, 2020
  • 1 location
Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis

With limited treatment options available for dermatomyositis, the investigators hypothesize that apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, is a safe and efficacious add-on treatment in patients with refractory cutaneous dermatomyositis. The study will investigate the efficacy, safety and toxicity of apremilast given at 30 mg twice daily to patients with refractory …

  • 10 Dec, 2020
  • 1 location